Phagenesis

Manchester, United Kingdom

Phagenesis is engaged in the development of a device to treat dysphagia, a condition that disables the safe swallowing of food.

$42.0M raised

Mar 2024

Series D

Biotechnology Health Care Medical

Top Investors

Northern GritstoneEQT Life SciencesAphelion CapitalInventages Venture Capital Investment Inc.British Patient Capital

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Phagenesis

How much funding has Phagenesis raised?

Phagenesis has raised $42.0M in total funding. The most recent round was Series D. The last funding was announced in March 2024.

Who are Phagenesis's investors?

Phagenesis's investors include Northern Gritstone, EQT Life Sciences, Aphelion Capital, Inventages Venture Capital Investment Inc., British Patient Capital.

Where is Phagenesis headquartered?

Phagenesis is headquartered in Manchester, United Kingdom.

What does Phagenesis do?

Phagenesis is engaged in the development of a device to treat dysphagia, a condition that disables the safe swallowing of food.

What stage is Phagenesis at?

Phagenesis is at the Series D stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated March 4, 2024.

MLA

"Phagenesis — Funding & Investors." VCBacked, March 4, 2024, https://www.vcbacked.co/company/phagenesis. Accessed June 4, 2026.

APA

VCBacked. (2024). Phagenesis — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/phagenesis

Wikipedia (cite web)

{{cite web |title=Phagenesis — Funding & Investors |url=https://www.vcbacked.co/company/phagenesis |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated March 4, 2024.

Similar Companies in Biotechnology